December 18, 2020 07:04 AM ESTUpdated 11:59 AM
R&D
Coronavirus

No­var­tis' biotech part­ner ad­mits PhI­II Covid-19 de­feat for stem cell ther­a­py, trig­ger­ing ex­ten­sion of $1.2B+ deal close

Amber Tong

The lat­est cell ther­a­py pro­gram to en­ter No­var­tis’ pipeline has flunked its first Phase III test for ven­ti­la­tor-de­pen­dent Covid-19 pa­tients with mod­er­ate to se­vere acute …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times